Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.63 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.63 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | ALPL | P05186 | 1/20 | 0.57 |
| ▸ | ALPI | P09923 | 1/20 | 0.57 |
| ▸ | ALPG | P10696 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5639911 | 0.98 | HDAC1 (0.61) | HDAC1HDAC2TAAR1MEN1KMT2A | |
| SCHEMBL4412374 | 0.91 | CYP1A2 (0.67) | HDAC1HDAC2MEN1KMT2ATSHR | |
| Hydrochloric Acid SCHEMBL7190843 | 0.89 | CYP1A2 (0.65) | HDAC1HDAC2MEN1KMT2ATSHR | |
| SCHEMBL6189108 | 0.85 | CYP1A2 (0.55) | HDAC1HDAC2MEN1KMT2ATSHR | |
| SCHEMBL15336407 | 0.84 | HDAC1 (0.87) | HDAC1HDAC2TAAR1MEN1KMT2A | |
| SCHEMBL15903879 | 0.83 | ALDH1A1 (0.47) | HDAC1HDAC2TAAR1MEN1KMT2A | |
| SCHEMBL4072168 | 0.83 | CA1 (0.54) | MAPK1L3MBTL1ALDH1A1LMNACYP3A4 | |
| SCHEMBL353032 | 0.82 | HPGD (0.63) | HDAC1HDAC2TAAR1MEN1KMT2A | |
| SCHEMBL1326062 | 0.81 | PARP10 (0.61) | HDAC1HDAC2TAAR1HPGDL3MBTL1 | |
| SCHEMBL4411547 | 0.81 | MMP3 (0.54) | MEN1KMT2ATSHRL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299104-B2 | Melanin hormone antagonist; therapy for obesity, type-2 diabetes | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-10-30 | — | — | US | disclosed |
| EP-1711494-B1 | ARYL SUBSTITUTED HETEROCYCLES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-06-09 | — | — | EP | disclosed |
| US-20080207707-A1 | ARYL-SUBSTITUTED HETEROCYCLES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-08-28 | — | — | US | disclosed |
| US-7319108-B2 | Aryl-substituted heterocycles, process for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-01-15 | — | — | US | disclosed |
| EP-1711494-A1 | ARYL SUBSTITUTED HETEROCYCLES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-10-18 | — | — | EP | disclosed |
| US-20050176710-A1 | Aryl-substituted heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-08-11 | — | — | US | disclosed |
| WO-2005070925-A1 | ARYL SUBSTITUTED HETEROCYCLES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207707-A1 | ARYL-SUBSTITUTED HETEROCYCLES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | CYP11B1, CYP11B2, GPR119 | HDAC1 975/4885HDAC2 1035/4885TAAR1 1394/4885 |
| US-20050176710-A1 | Aryl-substituted heterocycles, process for their preparation and their use as medicaments | CYP11B1, CYP11B2, GPR119 | HDAC1 975/4885HDAC2 1035/4885TAAR1 1394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.